Pakistan’s pharmaceutical sector recorded its highest-ever annual profit of Rs. 42.2 billion in fiscal year 2026. The sector’s strong financial performance was supported by higher profit margins and lower financing costs.
According to data compiled by Topline Securities, the pharmaceutical sector’s annual profit increased by 28% year-on-year in FY26. Profit margins also reached a record 42.8% during the fiscal year.
The improvement came alongside a significant reduction in financing expenses. The sector’s finance costs declined by 42% compared with the previous fiscal year. This reduction helped companies improve their earnings and achieve higher overall profitability.
The latest figures highlight the sector’s continued earnings growth over several years. Between FY17 and FY26, the pharmaceutical sector recorded a compound annual growth rate of approximately 14% in profits.
This growth reflects a sustained increase in earnings across the nine-year period. The record profit reported in FY26 further highlights the sector’s financial performance during the latest fiscal year.
However, the increase in profits did not lead to a similar rise in market value. The sector’s combined market capitalization grew by only 2% year-on-year as of June 30, 2026.
The difference between earnings growth and market capitalization indicates a gap between the sector’s financial performance and its overall market valuation. While annual profits increased by 28%, the combined market value recorded a much smaller gain.
Market capitalization represents the total market value of a company’s outstanding shares. For the pharmaceutical sector, the limited increase suggests that stronger earnings were not matched by an equivalent rise in the combined value of listed companies.
The figures present two different aspects of the sector’s performance in FY26. On one hand, pharmaceutical companies reported record profits, improved margins, and lower financing costs. On the other, their combined market capitalization experienced only modest growth.
The sector’s profit growth over the past nine years also points to a longer-term trend of rising earnings. However, the available figures do not explain the reasons behind the limited increase in market capitalization.
In other related news also read Pakistan Approves Interest-Free Hajj Savings Plan
Overall, Pakistan’s pharmaceutical sector closed FY26 with record annual profits of Rs. 42.2 billion. Higher profit margins and a sharp decline in finance costs supported the increase. Despite these gains, the sector’s combined market capitalization rose by just 2% year-on-year by the end of June 2026.
